Citations

Clear

861 citation(s) found for "Sd, Wexner".

Process mapping strategies to prevent subcutaneous implantable cardioverter‐defibrillator infections
Weiss, Raul , Mark, George E., Lambiase, Pier D. , Miller, Marc A. , McClernon, Timothy R., Knight, Bradley P. , El-Chami, Mikhael F , Miller, Marc A , Lambiase, Pier D , Knight, Bradley P , Weiss, Raul , El‐Chami, Mikhael F. , Biffi, Mauro , Probst, Vincent , Hansen, Linda K. , Baddour, Larry M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | June 4, 2022 | Volume: 33 | Issue: 7 | Pages: 1628-1635

10.1111/jce.15566 | PMID 35662315 Get It

AbstractBackgroundInfection remains a major complication of cardiac implantable electronic devices and can lead to significant morbidity and mortality. Implantable devices that avoid transvenous leads, such as the subcutaneous implantable cardioverter‐defibrillator (S‐ICD), can reduce the risk of serious infection‐related complications, such as bloodstream infection and infective endocarditis. While the 2017 AHA/ACC/HRS guidelines include recommendations for S‐ICD use for patients at high risk of infection, currently, there are no clinical trial data that address best practices for the prevention of S‐ICD infections. Therefore, an expert panel was convened to develop a consensus on these topics.MethodsAn expert process mapping methodology was used to achieve consensus on the appropriate steps to minimize or prevent S‐ICD infections. Two face‐to‐face meetings of high‐volume S‐ICD implanters and an infectious diseases specialist, with expertise in cardiovascular implantable electronic device infections, were conducted to develop consensus on useful strategies pre‐, peri‐, and postimplant to reduce S‐ICD infection risk.ResultsExpert panel consensus on recommended steps for patient preparation, S‐ICD implantation, and postoperative management was developed to provide guidance in individual patient management.ConclusionAchieving expert panel consensus by process mapping methodology for S‐ICD infection prevention was attainable, and the results should be helpful to clinicians in adopting interventions to minimize risks of S‐ICD infection.
Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysis
Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , D’Urso, Pietro Ivo , Quiñones‐Hinojosa, Alfredo , Trifiletti, Daniel M , Roncaroli, F , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , Hamer, Philip C. De Witt , Trifiletti, Daniel M. , Wesseling, Pieter , Borst, Gerben R.

Mayo Clinic

Neuro-Oncology Advances | June 4, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac075 | PMID 35769410 Get It

Abstract Background In patients with newly diagnosed glioblastoma, rapid early progression (REP) refers to tumor regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis appraised previously published data on REP to better characterize and understand it. Methods Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to October 21, 2021. Studies describing the incidence of REP—tumor growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly diagnosed glioblastoma were included. The primary outcome was REP incidence. Results From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0–58.8 y). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1–1.5). The median number of days between MRI scans was 34 days (IQR 18–45 days). The mean incidence rate of REP was 45.9% (range 19.3%–72.0%) and significantly lower in studies employing functional imaging to define REP (P < .001). REP/non-REP groups were comparable with respect to age (P = .99), gender (P = .33) and time between scans (P = .81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30–2.43, P < .001), shortened progression-free survival (HR 1.78, 95% CI 1.30–2.43, P < .001), subtotal resection (OR 6.96, 95% CI 4.51–10.73, P < .001) and IDH wild-type versus mutant tumors (OR 0.20, 95% CI 0.02–0.38, P = .03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72–2.28, P = .39). Conclusions REP occurs in almost half of patients with newly diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
0363 Perceptions of the Need for Perioperative OSA Education: An Interdisciplinary and Multi-Institutional Survey
Gali, Bhargavi , Auckley, Dennis , Myers, John C., Charchaflieh, Jean , Yılmaz, Meltem , Khan, Meena , Card, Elizabeth , Gelfand, Brain, Pilla, Michael A., Loftsgard, Theodore O. , Matura, Lea Ann , Carlucci, Melissa , Sahni, Ashima , Glaser, Kathleen, Ghussain, Dana Al, Rosen, Ilene M. , Lyons, M. Melanie , Mokhlesi, Babak , Williams, Lisa, Sawyer, Amy M. , Brock, Guy , Magalang, Ulysses J , Pack, Allan I

Mayo Clinic

Sleep | May 31, 2022 | Volume: 45 | Issue: Supplement_1 | Pages: A163-A164

10.1093/sleep/zsac079.360 Get It

Abstract Introduction Advanced Practice Providers (APPs; Advanced practice registered nurses, physician assistants) and physicians-in-training (residents, fellows) receive inadequate education on obstructive sleep apnea (OSA)/perioperative OSA risks. However, they are front-line providers assessing these patients. Failure to mitigate this risk has led to significant postoperative morbidity/mortality. We assessed these providers’ perceptions to OSA/perioperative OSA training. Methods Surveys were sent to three provider roles, APPs, residents, and fellows, in four categories of practice at nine academic institutions between May 9-June 30, 2021. Chi-square and Fisher’s exact tests assessed association between survey responses and participant characteristics. False discovery rate adjustment accounted for multiple comparisons, threshold of q<0.05 for statistical significance. Cochran-Mantel-Haenzsel tests evaluated associations stratified by institution. Results 2236 of 6724 (33.3%) participants responded: 48.4% APPs, 11% Fellows and 40.6% Residents. Primary category of practice included: 20.3% Anesthesiology, 8.9% Family Medicine, 34.1%, Internal Medicine (IM)/IM subspecialties, 6.7% Obstetrics/Gynecology/Gynecologic Oncology, 25.9% Surgery/Surgery subspecialties, 4.1% Other.While 93.2% of respondents believed OSA is a risk factor for perioperative complications, fewer respondents reported that they felt adequately trained to assess for OSA (50.9%) in general, with significant differences noted by provider role (range 42-70%, q=0.001) and across the categories of practice (range 12-82%, q=0.001). Even fewer felt adequately trained to assess for OSA in perioperative patients (38.2%) with significant differences noted by provider role (range 31-52%, q=0.001) and across the categories of practice (range 15-84%, q=0.001).Across all categories of practice, respondents indicated that they would like additional educational training about OSA (76.7%). This varied by clinical role (range 64-82%, q=0.003), but not categories of practice (range 73-84%, q=0.13). Furthermore, respondents indicated they also desired additional education about OSA in the perioperative patient (75.5%). This extended across all clinical roles (range 68-77%, q=0.09) and categories of practice (range 72-80%, q=0.09). Conclusion We found significant differences in APP and physician-in-training perceptions of the adequacy of their current training and desire for further OSA/perioperative OSA education. Our study identifies a critical gap and opportunity to improve provider understanding and patient care. Support (If Any) American Academy of Sleep Medicine Foundation (AASMF) award.
A 44-year-Old Male with Esophageal Ulcer
Fogwe, Delvise T. , Aditya, Shah, Ho, Matthew

Mayo Clinic

No container title available | April 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165028333.35367568/v1 Get It

Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
Dulai, Parambir S. , Raffals, Laura E. , Kochhar, Gursimran , Damas, Oriana M. , Sauk, Jenny , Levy, Alexander N., Sofia, M. Anthony , Tuskey, Anne , Deepak, Parakkal , Yarur, Andrés , Afzali, Anita , Deepak, Parakkal , Yarur, Andres J , Rai, Victoria , Lukin, Dana J. , Hudesman, David , Ananthakrishnan, Ashwin N. , Cross, Raymond K. , Hanauer, Stephen B. , Siegel, Corey A

Mayo Clinic

American Journal of Gastroenterology | April 13, 2022 | Volume: 117 | Issue: 8 | Pages: 1288-1295

10.14309/ajg.0000000000001775 | PMID 35416799 Get It

INTRODUCTION: Limited guidance exists for the postdischarge care of patients with ulcerative colitis hospitalized for moderate-severe flares. METHODS: RAND methodology was used to establish appropriateness of inpatient and postdischarge steroid dosing, discharge criteria, follow-up, and postdischarge biologic or small molecule initiation. A literature review informed on the panel's voting, which occurred anonymously during 2 rounds before and after a moderated virtual session. RESULTS: Methylprednisolone 40–60 mg intravenous every 24 hours or hydrocortisone 100 mg intravenous 3 times daily is appropriate for inpatient management, with methylprednisolone 40 mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has resolved (Mayo subscore 0–1) and/or stool frequency has returned to baseline frequency and form (Mayo subscore 0–1). It is appropriate to discharge patients on 40 mg of prednisone after observing patients for 24 hours in hospital to ensure stability before discharge. For patients being discharged on steroids without in-hospital biologic or small molecule therapy initiation, it is appropriate to start antitumor necrosis factor (TNF) therapy after discharge for anti-TNF-naive patients. For anti-TNF-exposed patients, it is appropriate to start vedolizumab or ustekinumab for all patients and tofacitinib for those with a low risk of adverse events. It is appropriate to follow up patients clinically within 2 weeks and with lower endoscopy within 4–6 months after discharge. DISCUSSION: We provide recommendations on the inpatient and postdischarge management of patients with ulcerative colitis hospitalized for moderate-severe flares.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Achufusi, Amaka, Armand, Philippe , Bhatia, Shailender , Chokshi, Saurin , Davies, Marianne, Elshoury, Amro, Gesthalter, Yaron , Kaffenberger, Benjamin H. , Li, Tianhong , Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Oluwole, Olalekan O. , Patel, Sandip Pravin , Patil, Pradnya D. , Reddy, Sunil , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Lyons, Megan , Dwyer, Mary A., Hang, Lisa, Oluwole, Olalekan O , Kaffenberger, B , Ryder, Mabel , Berkenstock, Meghan , Budde, Lihua E. , Hegde, Aparna , Jain, Michael D. , Lechner, Melissa G , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2022 | Volume: 20 | Issue: 4 | Pages: 387-405

10.6004/jnccn.2022.0020 | PMID 35390769 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visitNCCN.org.
766 12-year Analysis of Gender Disparity in Authorship of Peer-Reviewed Burn and Wound Care Literature
Khan, Iman F. , Ketheeswaran, Suvethavarshini, Turker, Ismail, Alasgarov, Elvin, Wiley, Brea, Guliyeva, Günel , Turker, Ismail

Mayo Clinic

Journal of Burn Care & Research | March 25, 2022 | Volume: 43 | Issue: Supplement_1 | Pages: S190-S190

10.1093/jbcr/irac012.319 Get It

Abstract Introduction The importance of gender equity and gender representation in academic publications has long been emphasized in medicine. It has been established that women represent a smaller proportion of primary and senior authors in high-impact medical journals than men and that original research articles written by women as primary and senior authors are less frequently sited than those authored by men. Currently, there is limited data evaluating whether this gender bias is present in plastic surgery and burn publications. We used bibliometric analysis of original research publications to analyze gender bias against women in one burn journal. Methods Using the journal, Burns, we conducted a bibliometric analysis of research publications from 2009 to 2020. A gender determining application was used to characterize the gender of the first and senior author. Ratios of male:male, female:male, male:female, and female:female were obtained and analyzed. Results Of the 1677 publications included, 40% have female first authors and 25.5% had female senior authors. Male:male authorships had the highest number of publications. Female:female authorship had the lowest number of publications of all the other ratios from 2009-2012, however there was a steep increase in 2013 in which male:female authorship had the lowest number of publications. Male senior authorship was associated with 2.9-fold increase in male first authorship [OR=2.99(95% CI 2.39, 3.76); p < 0.0001). Conclusions Female representation in senior authorship positions in burn and wound care publications is increasing, however is still far from reaching gender parity. By analyzing authorship ratios by gender, we recommend a new way to evaluate gender disparity in burn and wound care academia.